Start Over

Anti-tumor Effects of Cyclolinopeptide on Giant-cell Tumor of the Bone.

Authors :: Taniguchi Y
Yamamoto N
Hayashi K
Takeuchi A
Miwa S
Igarashi K
Higuchi T
Abe K
Yonezawa H
Araki Y
Morinaga S
Kamei J
Nugroho AE
Kaneda T
Morita H
Tsuchiya H
Source :: Anticancer research [Anticancer Res] 2019 Nov; Vol. 39 (11), pp. 6145-6153.
Publication Year :: 2019
Abstract: Aim: This study aimed to evaluate the antitumor effects of cyclolinopeptide (CL), which suppresses receptor activator of nuclear factor-κB ligand (RANKL) signalling on giant-cell tumours of the bone (GCTB) cells.<br />Materials and Methods: GCTB cell lines were established, and the inhibition of cell growth by CL was evaluated using the water-soluble tetrazolium salt-8 cell proliferation assay, cell cycle assay, and 5-ethynyl-2'-deoxyuridine (EdU) cell proliferation assay. RANKL and runt-related transcription factor 2 (RUNX2) expression levels were evaluated using real-time polymerase chain reaction before and after CL administration.<br />Results: The dose-dependent inhibition of GCTB cells was significantly pronounced in the CL-administered group compared to the non-CL-administered group (p<0.05). In the CL-administered group, the ratio of cells in the G <subscript>0</subscript> /G <subscript>1</subscript> phase was increased, but the ratio of EdU-positive cells was decreased (p<0.05). RANKL and RUNX2 levels were decreased in the CL-administered group (p<0.05).<br />Conclusion: CL has antitumor effects on GCTB in vitro.<br /> (Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)